Quantum BioPharma Ltd. (CSE:QNTM)
Canada · Delayed Price · Currency is CAD 4.510
+0.410 (10.00%)
At close: Sep 4, 2026
Quantum BioPharma Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
17
Market Cap
36.47M CAD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Microbix Biosystems | 15.40M |
| Telescope Innovations | 7.30M |
| Devonian Health Group | 3.00M |
| Onco-Innovations | 110.38K |
| The More Life Company | 70.00K |
Quantum BioPharma News
- 4 days ago - Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange - GlobeNewsWire
- 5 days ago - Quantum Group initiated with a Buy at Rodman & Renshaw - TheFly
- 15 days ago - Quantum Biopharma Provides Corporate Update - GlobeNewsWire
- 22 days ago - Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial - GlobeNewsWire
- 26 days ago - Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis: - GlobeNewsWire
- 5 weeks ago - Quantum BioPharma Announces Closing of Debt Settlement - GlobeNewsWire
- 6 weeks ago - Quantum BioPharma Announces Intention to Settle Debt - GlobeNewsWire
- 2 months ago - Quantum BioPharma Provides Corporate Update - GlobeNewsWire